Table 2 Baseline measurements of the included randomized controlled trials
Reference | Analyzed (n = 149) | VD3 Daily Dosage IU | Males (%) | Mean Age Years | 25(OH)D (ng/mL) | 25(OH)D (nmol/L) | 25(OH)D Method of Analysis | Lost to Follow-up |
|---|---|---|---|---|---|---|---|---|
Jung 2018 [30] | 20 | 5000 | 60% (21/35) | 20.1 ± 0.15 | 10.9 ± 0.47 | 27.3 ± 1.18 | CLIA analyzer (Liaison XL, Dasorin, Italy) | 9 |
15 | PL |  |  | 12.36 ± 0.78 | 30.9 ± 1.95 | (20.45%) | ||
Fairbairn 2018 [31] | 28 | 3570 | 100 | 21.5 ± 2.8 | 37.2 ± 7.6 | 93 ± 19 | LC-MS/MS at Canterbury Health Laboratories, Christchurch, New Zealand | 0 |
29 | PL |  | 20.9 ± 2.8 | 38 ± 6.8 | 95 ± 17 |  | ||
Close 2013b [32] | 5 | 5000 | 100 | 18 ± 5 | 11.6 ± 10 | 29 ± 25 | HPLC-MRM (Becton Dickinson, Oxford, UK) | 0 |
5 | PL |  |  | 21.2 ± 11.6 | 53 ± 29 |  | ||
Close 2013a [28] | 6 | 5714 | 100 | 21 ± 1 | 20.4 ± 10.4 | 51 ± 26 | HPLC-MRM (Becton Dickinson, Oxford, UK) | 5 |
10 | 2857 |  | 22 ± 2 | 21.2 ± 10.4 | 53 ± 26 | (16.70%) | ||
9 | PL |  | 21 ± 1 | 20.8 ± 10.8 | 52 ± 27 |  | ||
Wyon 2016 [29] | 11 | 18,750 | 100 | 29 ± 10.6 | 13.2 ± 3.8 | 32.8 ± 9.4 | ECLIA (Tecan Infinite F500, Mannedorf, Switzerland) | 0 |
11 | PL |  | 26 ± 7.4 | 16.3 ± 2.7 | 40.7 ± 6.8 |  |